CClinicalTrials.gg
CompletedNCT03520400PAUSEUpdated Feb 2, 2024Results posted

PCI Alternative Using Sustained Exercise

An interventional study of Exercise Therapy in Cardiovascular Disease, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 5 years 6 months after the study started (first participant enrolled Oct 2012, registered Apr 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

Cardiovascular disease remains the leading cause of morbidity and mortality in the U.S. and is a major cause of disability in Veterans. Most of these deaths are due to coronary artery disease (CAD). The most common treatment for CAD is revascularization, an invasive procedure which usually involves placing a stent inside an artery that is diseased. However, exercise training is often overlooked because clinicians tend to focus on repairing the coronary circulation and the potential need for revascularization. Studies have shown that exercise training can be effective for patients with CAD and that it saves costs. In this study, invasive revascularization will be compared to a structured program of exercise training over one year. Comparisons will be made between groups for symptoms, coronary artery size and function using PET/CTA, and health care cost utilization.

Read the detailed description

Despite advances in treatment options for cardiovascular disease (CVD), this condition remains the leading cause of morbidity and mortality in the U.S. and is a major cause of disability in Veterans. Percutaneous coronary intervention (PCI) is the treatment most often used in patients with various manifestations of coronary artery disease (CAD). While it is commonly assumed that PCI also reduces mortality, randomized trials have shown that PCI has no effect on mortality except in patients being treated for acute myocardial infarction. Over the last decade, the use of PCI has increased exponentially; between 1996 and 2007, the number of PCIs performed in the US has increased more than 4-fold, from approximately 300,000 to more than 1.3 million yearly. During this time, PCI has accounted for 10% of the overall increase in Medicare expenditures. In light of the extraordinary increase in the use of this technology in recent years, questions have been raised regarding the cost-effectiveness of PCI, the extent to which PCI is overused, and whether selected patients may benefit from optimal medical therapy in lieu of PCI. Cost analyses have suggested that the current rate of increase in PCI with DES is unsustainable for the U.S. healthcare system. Given the costs associated with PCI, there have been recent efforts to compare outcomes and effectiveness of PCI against non-invasive therapy.

There is a need to evaluate more judicious use of PCI, and to consider less costly interventions for at least some of the >1.3 million patients in the U.S. who undergo this procedure. Lifestyle intervention, including exercise training, is one option that has been shown to result in reduced symptoms, better exercise tolerance, improved quality of life and lower mortality. A growing body of data has demonstrated that exercise intervention improves coronary anatomy and lessens ischemia through enhanced endothelial function. While a significant proportion of health care expenditures are devoted to PCI and other invasive interventions for CVD, few health care resources are directed toward primary or secondary prevention. Recent studies have demonstrated that programs of cardiac rehabilitation, with and without implementation of intensive risk reduction, are cost effective. In part because of the financial interests associated with PCI, exercise and lifestyle intervention is rarely considered as a clinical treatment option in PCI candidates. A gap exists between the standard clinical treatment for CAD and the potential for non-invasive, less expensive and potentially more effective treatments for these patients. Previous efforts to quantify the effects of exercise and lifestyle intervention on coronary artery perfusion and anatomy have been limited to standard angiography. In recent years, improved technologies for imaging coronary perfusion and anatomy have been developed, which could provide important insights into the effects of exercise training on the heart. These include the combination of positron emission tomography and ultra-fast computed tomography angiography (CTA), commonly termed PET/CTA. PET provides information on the functional significance of anatomic stenoses by measuring myocardial blood flow and myocardial perfusion reserve. PET can also be used to evaluate coronary endothelial function by measurements of changes in myocardial blood flow in response to physical stimuli (i.e., cold pressor testing). The combination of CTA with PET also allows for improved attenuation correction. CTA, on the other hand, can noninvasively image the coronary arteries to determine the severity of stenosis and the amount of calcified and noncalcified plaque burden.

The investigators have termed the current proposal "PCI Alternative Using Sustained Exercise" (PAUSE) to reflect the potential for exercise training and lifestyle intervention as alternative therapies in selected PCI candidates.

Primary aim: To determine whether subjects with lesions amenable to PCI randomized to a 1 year exercise program and lifestyle intervention have greater improvement in coronary perfusion and function than those randomized to PCI.

Secondary analyses: The investigators will compare exercise test responses, health care costs, quality of life, and clinical outcomes between groups.

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Cardiovascular Disease
  • Percutaneous Intervention
  • coronary artery disease
  • exercise therapy
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's enrollment of 51 is below the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,733 studies on the registry; 396 are open to participants now.

Of its 206 completed or terminated interventional studies of FDA-regulated products, 180 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Stable patients who have lesions appropriate for PCI based on American Heart Association/American College of Cardiology criteria will be considered for the study.
  • Only patients with a good prognosis (annual mortality \<2% based on VA multivariate scores (57, 58) will be considered.

Exclusion criteria

Exclusion Criteria:

  • Patients with left main disease or proximal LAD disease, or:

    • Unstable angina
    • A history of left ventricular dysfunction (EF 30%)
    • Pacemakers
    • Atrial fibrillation
    • Myocardial infarction within the last 3 months
    • Diabetes
    • Orthopedic problems interfering with the ability to exercise regularly
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Exercise Intervention Group

    Group receives one year of exercise and lifestyle intervention

    Behavioral: Exercise Therapy

  • No intervention
    PCI group (usual care)

    Group receives standard clinical care with no intervention

Interventions

  • BehavioralExercise Therapy

    Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.

    Also known as: Exercise Training

06

What researchers measure

Primary outcomes

  1. Myocardial Perfusion Reserve

    Measurement of myocardial blood flow has only been analyzed at baseline at this time. Intravenous 13NH3 will be used as the flow tracer and serial imaging with PET will be performed. Measurements will be performed at baseline, and after pharmacologic stress with dipyridamole. Myocardial blood flow at rest and following dipyridamole infusion will be expressed as ml flow/100 g/min. The myocardial perfusion reserve will be calculated as the ratio of the myocardial blood flow during stress (e.g. after dipyridamole) and the myocardial blood flow at rest. Commercially available software (Emory tool box) will be used to quantitatively analyze PET myocardial perfusion images.

    Time frame: baseline and 1 year

Secondary outcomes

  1. Peak VO2

    Peak VO2 will be determined at baseline and 1 year on a treadmill using an individualized ramp protocol with collection of continuous ventilatory gas exchange responses.

    Time frame: baseline and after 1 year

07

Results

Posted Sep 20, 2021

Participant flow

Participant flow — Overall Study
MilestoneExercise Intervention GroupPCI Group (Usual Care)
Started3714
Completed227
Not completed157
Withdrew: Physician decision157

Outcome measures

PrimaryMyocardial Perfusion Reserve

Measurement of myocardial blood flow has only been analyzed at baseline at this time. Intravenous 13NH3 will be used as the flow tracer and serial imaging with PET will be performed. Measurements will be performed at baseline, and after pharmacologic stress with dipyridamole. Myocardial blood flow at rest and following dipyridamole infusion will be expressed as ml flow/100 g/min. The myocardial perfusion reserve will be calculated as the ratio of the myocardial blood flow during stress (e.g. after dipyridamole) and the myocardial blood flow at rest. Commercially available software (Emory tool box) will be used to quantitatively analyze PET myocardial perfusion images.

Time frame:
baseline and 1 year
Reported as:
Mean · Ratio
Myocardial Perfusion Reserve
RatioExercise Intervention GroupPCI Group (Usual Care)
Baseline2.76 ± 0.612.47 ± 0.48
1-year2.82 ± 0.562.52 ± 0.43
SecondaryPeak VO2

Peak VO2 will be determined at baseline and 1 year on a treadmill using an individualized ramp protocol with collection of continuous ventilatory gas exchange responses.

Time frame:
baseline and after 1 year
Reported as:
Mean · ml/kg/min
Peak VO2
ml/kg/minExercise Intervention GroupPCI Group (Usual Care)
Baseline20.21 ± 3.7619.85 ± 6.5
1 Year22.4 ± 4.1018.91 ± 5.92

Adverse events

Collected over 1-year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exercise Intervention Group0/37 (0%)0/37 (0%)0/37 (0%)
PCI Group (Usual Care)0/14 (0%)0/14 (0%)0/14 (0%)

Baseline characteristics

Subjects with suspected coronary artery disease undergoing percutaneous coronary intervention

Age, Categorical
Age, Categorical(Participants)Exercise Intervention GroupPCI Group (Usual Care)Total
<=18 years000
Between 18 and 65 years729
>=65 years15520
Age, Continuous
Age, Continuous(years)Exercise Intervention GroupPCI Group (Usual Care)Total
Mean66.6 ± 3.869.0 ± 7.367.4 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Exercise Intervention GroupPCI Group (Usual Care)Total
Female000
Male22729
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Exercise Intervention GroupPCI Group (Usual Care)Total
American Indian or Alaska Native101
Asian415
Native Hawaiian or Other Pacific Islander213
Black or African American314
White12416
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Exercise Intervention GroupPCI Group (Usual Care)Total
United States22729
08

Study locations

1 site
  • VA Palo Alto Health Care System, Palo Alto, CA
    Palo Alto, California 94304-1290, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 3, 2010

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Upon completion of the study, de-identified data will be made available to collaborative institutions with whom the investigators are in contact.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03520400
Lead sponsor
VA Office of Research and Development
Responsible party
Sponsor
First posted
May 9, 2018
Start date
Oct 1, 2012
Primary completion
Sep 30, 2019
Completion
Sep 30, 2019
Results posted
Sep 20, 2021
Last update
Feb 2, 2024

Study contacts

Jonathan N Myers, PhD
principal investigator · VA Palo Alto Health Care System, Palo Alto, CA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion